#United States #Santa Clara #Clinical Research #ACL Digital #Symbiance

ACL Digital Expands Clinical Research Footprint with Symbiance Acquisition

ACL Digital, a prominent name in digital product innovation, has made a significant leap in the clinical research sector by acquiring Symbiance, a well-established Contract Research Organization (CRO) headquartered in the United States. Symbiance brings over three decades of experience and expertise in areas such as clinical data services, medical monitoring, and pharmacovigilance.

The acquisition, announced on September 26, 2025, marks a strategic move by ACL Digital as it seeks to enhance its global presence and service offerings in clinical research. With this acquisition, ACL Digital reinforces its position not just as a provider of clinical research solutions, but as a comprehensive, end-to-end CRO capable of addressing the diverse needs of clients in the pharmaceutical, biotech, and medical device industries.

Strengthening Life Sciences Portfolio

Ramandeep Singh, CEO of ACL Digital, has expressed excitement about this acquisition, emphasizing its alignment with the company's growth strategy. He highlighted that integrating Symbiance into ACL Digital's operations will enable the company to offer innovative, patient-centered solutions that meet and exceed industry standards. This partnership is poised to enhance operational efficiency and innovation, driving ACL Digital towards its goal of providing cutting-edge solutions in clinical research.

In the fast-evolving landscape of life sciences, the demand for AI-driven solutions is paramount. The combination of ACL Digital's AI capabilities with Symbiance's detailed domain expertise in clinical data management presents a unique opportunity to meet this need. The symbiosis of these two entities is expected to empower clients to adopt intelligent, data-driven strategies that can lead to improved patient outcomes and operational efficiencies.

Enhancing Client Services Through Innovation

Sreejith Narayanan, Senior Vice President of Sales and Operations at ACL Digital, acknowledged Symbiance’s robust reputation in the US market, attributing the company’s success to its focus on quality and timely delivery. He reiterated that this acquisition is not merely a growth strategy but a commitment to advancing as a leader in providing digital solutions tailored for clinical research.

The emphasis on quality service and expertise is echoed by Ilango Ramanujam, President and CEO of Symbiance, who expressed enthusiasm about joining forces with ACL Digital. He highlighted that their distinct 'people + product' delivery method, complemented by proprietary tools and AI-driven analytics, will significantly enhance the service offerings of ACL Digital amidst the competitive landscape of clinical research.

A Vision for the Future

Looking forward, both companies are set to work collaboratively to leverage their resources and expertise in a way that not only nurtures existing client relationships but also draws in new partners. The integration of Symbiance is expected to provide ACL Digital with enhanced capabilities to innovate and adapt to the evolving needs of its clients, reinforcing the company's commitment to improving the standard of clinical research and data services.

As a subsidiary of the ALTEN Group, ACL Digital is not new to operational excellence in the tech landscape. It provides a broad range of services across various sectors, including telecom, media, and technology, all while maintaining a focus on AI-powered, cloud-native solutions that drive modernization and transformation.

In conclusion, the acquisition of Symbiance represents a pivotal moment for ACL Digital as it underscores its dedication towards becoming a global leader in digital transformation for clinical research and beyond. With a robust strategy for growth and innovation firmly in place, the company is well-equipped to meet the challenges and opportunities that lie ahead in the field of life sciences.

For more information, please visit ACL Digital.